Search
Carboplatin Treatment Options
A collection of 1669 research studies where Carboplatin is the interventional treatment. These studies are located in the United States. Carboplatin is used for conditions such as Non-Small Cell Lung Cancer, Ovarian Cancer and Lung Cancer.
1177 - 1188 of 1669
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
Completed
This study is being done to test whether panitumumab, in combination with chemotherapy and radiation is safe in people with head and neck cancer. Another goal of this study is to find the highest dose of the study drugs that can be given safely without causing serious sife effects. Panitumumab is a type of drug called a monoclonal antibody that has been studied in other types of cancers, such as kidney and colon. This monoclonal antibody is directed against the epidermal growth factor receptor (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2017
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Squamous Cell Carcinoma of the Head and Neck
Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma
Unknown
Initially, the prospect of metformin as a neoplastic treatment was considered for malignancies of the prostate, colon and pancreas. However, only select clinical studies involving the use of metformin in the treatment of ovarian cancer have documented improved survival rates. Since no first line regimen has demonstrated compelling superiority in the management of advanced stage ovarian carcinoma, the combination of paclitaxel, carboplatin, and metformin is of particular interest given the triple... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/24/2017
Locations: Gynecologic Oncology Associates, Newport Beach, California
Conditions: Epithelial Ovarian Carcinoma
Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer
Completed
The purpose of this research study is to learn more about whether the combination of drugs carboplatin, Abraxane and Avastin helps treat non-small cell lung cancer (NSCLC). One of the standard treatments for advanced NSCLC is the combination of the drugs carboplatin, paclitaxel and Avastin. Paclitaxel can be associated with severe side effects that may make the treatment difficult to tolerate. Some of these side effects are caused by the solution used to dissolve paclitaxel before it can be admi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2017
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Non-small Cell Lung Cancer
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Terminated
The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/22/2017
Locations: Research Site, Birmingham, Alabama +309 locations
Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors
Completed
This is a dose-finding study; therefore, there is no hypothesis testing
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/22/2017
Locations: Pfizer Investigational Site, Los Angeles, California +3 locations
Conditions: Neoplasms
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
Terminated
The purpose of this research study was to evaluate how effective the combination of Carboplatin, Bevacizumab (Avastin™) and, Pemetrexed (Alimta™) is in the treatment of patients with Malignant Pleural Mesothelioma (MPM). A combination of cisplatin and pemetrexed is considered standard for this disease and typically off protocol patients would receive cisplatin or carboplatin and pemetrexed as standard of care.
The planned length of the study (first patient screened to last patient enrolled) was... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2017
Locations: H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
Conditions: Mesothelioma
The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Completed
The standard treatment for non-small cell lung cancer, stage IV or IIIB malignant pleural effusion is chemotherapy. The decision to use a regimen is currently determined by toxicity or by physician's preference. In this protocol, the treatment regimen will be assigned based on the patients' tumor molecular profile. A tumor molecular profile analysis will allow the physician to define a specific molecular portrait that shows the genetic basis of the tumor. This analysis results in a detailed repo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2017
Locations: H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
Conditions: Carcinoma, Non-Small-Cell Lung
Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC
Completed
This is a single institution Phase II study for patients with unresectable Stage IIIA and IIIB non-small cell lung cancer. The treatment started with 2 cycles of gemcitabine and carboplatin followed by concurrent chemotherapy with radiation. The chemoradiation included using paclitaxel and carboplatin with daily thoracic radiation to a total dose of 74 Gy. Response rate was determined following the chemotherapy with gemcitabine and carboplatin and evaluated again after the chemoradiation. Treatm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2017
Locations: H. Lee Moffitt Cancer Center & Research Insitute, Tampa, Florida
Conditions: Lung Cancer
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well carboplatin given together with paclitaxel and everolimus works in treating patients with previously untreated... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2017
Locations: Poudre Valley Hospital, Fort Collins, Colorado +140 locations
Conditions: Carcinoma of Unknown Primary Origin
Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving gemcitabine and carboplatin together with AZD2171 may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying how well giving gemcitabine... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2017
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +153 locations
Conditions: Lung Cancer
Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer
Terminated
The aim of this study is to combine AZD1775 with standard front-line chemotherapy in subjects with advanced NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2017
Locations: Research Site, Englewood, Colorado +7 locations
Conditions: Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Completed
To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies resistant to standard therapy.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/09/2017
Locations: Research Site, Los Angeles, California +9 locations
Conditions: Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
1177 - 1188 of 1669